AtaiBeckley extends cash runway to 2029 as key mental health trials advance

AtaiBeckley (NASDAQ:ATAI) reported a strong liquidity position and clear clinical timeline in its first-quarter results, reassuring investors that its current cash reserves of $209.9 million are sufficient to fund operations into early 2029.

This runway is expected to cover several critical data readouts, including the pivotal Phase 3 results for its lead depression candidate.

The company is preparing to launch a two-study Phase 3 program for BPL-003, an intranasal formulation of mebufotenin benzoate, in the second quarter of 2026.

The trials, named ReConnection-1 and ReConnection-2, follow a successful End-of-Phase 2 meeting with the FDA and will target patients with treatment-resistant depression (TRD).

Management expects topline data from these core pivotal studies by early 2029.

Beyond its lead program, AtaiBeckley confirmed that the Phase 2 "Elumina" trial of VLS-01—a buccal film delivery of DMT for TRD—remains on track for a topline readout in the second half of 2026.

The company also highlighted expanded Phase 2a data for EMP-01 (oral R-MDMA), which showed a 49% responder rate and significant improvements in social anxiety symptoms and real-world avoidance behavior.

Financial results for the quarter reflected the intensive clinical activity, with a net loss of $29.8 million.

The loss was driven by a planned increase in research and development expenses as the company ramps up Phase 3 readiness and administrative costs related to global operations.